• Olaparib (AZD2281): Applied Workflows for DNA Damage Respons

  2026-08-05

  Olaparib (AZD2281) empowers precision DNA damage response and tumor radiosensitization workflows, especially in BRCA-deficient and spliceosome-modulated cancer models. This article translates the latest mechanistic insights into actionable guidance, protocol optimization, and troubleshooting strategies for advanced cancer research.

• BicD and MAP7 Cooperate to Activate Drosophila Kinesin-1

  2026-08-04

  This study demonstrates that Drosophila BicD and MAP7 activate homodimeric kinesin-1 through complementary mechanisms, revealing that BicD relieves kinesin autoinhibition while MAP7 enhances microtubule engagement. The findings refine our understanding of motor adaptor collaboration and have practical implications for reconstituting and dissecting motor protein complexes in vitro.

• Fucoidan (C4038): Anticancer Mechanisms, Evidence, and Proto

  2026-08-04

  Fucoidan is a sulfated α-L-fucan from brown seaweed with verified anticancer and immune-modulating effects. Mechanistically, it induces apoptosis in cancer cells and suppresses angiogenesis in vivo. This article details its molecular actions, benchmarks, and best-practice workflow integration.

• Translational Acceleration with DiscoveryProbe Bioactive Lib

  2026-08-03

  This article examines the mechanistic and strategic imperatives for translational researchers leveraging the DiscoveryProbe™ Bioactive Compound Library Plus (SKU: L1022P) from APExBIO. By bridging advances in ligand discovery—such as thermal shift assays for bacterial sensor proteins—with high-throughput screening in oncology, immunology, and signal transduction, the article provides a roadmap for integrating mechanistic rigor, workflow efficiency, and competitive differentiation. Protocol parameters, practical limitations, and a forward-looking outlook are included, addressing the complex demands of contemporary translational research.

• Fucoidan Downregulates Caveolin-1 in MCF-7 Breast Cancer Cel

  2026-08-03

  This study reveals that fucoidan, a sulfated α-L-fucan from brown seaweed, selectively suppresses caveolin-1 expression in MCF-7 breast cancer cells, suggesting a novel mechanism underlying its antitumor effects. The findings highlight caveolin-1 as a potential therapeutic target and reinforce fucoidan's promise as a natural, low-toxicity anticancer polysaccharide.

• DeferoxamineB: Optimizing Iron Chelation in Cancer Research

  2026-08-02

  DeferoxamineB streamlines advanced cancer research by enabling robust, reproducible iron chelation and regulated cell death modeling. This guide translates metabolic intervention breakthroughs into practical protocols, troubleshooting, and next-generation applications for oncology and beyond.

• AKTIP as a Biomarker for Fibrolamellar Carcinoma: WGCNA and

  2026-08-01

  This study identifies AKTIP as a robust diagnostic and prognostic biomarker for fibrolamellar carcinoma (FLC) using integrated weighted gene co-expression network analysis (WGCNA) and machine learning. The work provides evidence for AKTIP's clinical relevance and proposes new avenues for targeted therapeutic strategies in this rare liver cancer subtype.

• ORAI2-Mediated Calcium Entry Drives Early Salivary Gland Fib

  2026-07-31

  This study identifies ORAI2-mediated store-operated calcium entry (SOCE) as a central mechanism in early-stage postirradiation fibrosis of salivary glands. By mapping the ORAI2/JNK/NFAT1/TGF-β1 axis and showing that pharmacological SOCE inhibition mitigates fibrogenesis and restores gland function, the research provides new molecular targets and workflow strategies for addressing radiation-induced hyposalivation.

• Moxidectin: Macrocyclic Lactone Anthelmintic for Antifungal

  2026-07-31

  Moxidectin, a macrocyclic lactone anthelmintic, is now proven to synergize with polyene antifungals by boosting ergosterol biosynthesis in Candida albicans, offering a powerful strategy for overcoming drug resistance and toxicity in oral candidiasis models. This article delivers actionable experimental workflows and troubleshooting tips for leveraging high-purity Moxidectin from APExBIO in advanced antifungal research.

• Fasudil (HA-1077) HCl: ROCK Inhibitor Workflows & Pitfalls

  2026-07-30

  Fasudil (HA-1077) HCl offers selective, reproducible ROCK pathway inhibition for precise studies of cell proliferation, migration, and apoptosis. This guide translates bench-proven protocols and advanced troubleshooting tips, empowering researchers to exploit Fasudil’s unique advantages—especially for cancer and hematological models.

• Paroxetine Mesylate Targets MET and ERBB3 in Colon Cancer Ce

  2026-07-30

  This study demonstrates that Paroxetine Mesylate, a selective serotonin reuptake inhibitor, exerts anticancer effects in human colorectal cancer cells by inhibiting receptor tyrosine kinases MET and ERBB3. These findings highlight drug repurposing potential and offer mechanistic insight into multi-targeted approaches for colorectal cancer.

• Fucoidan: Multi-Pathway Strategies for Translational Success

  2026-07-29

  Explore how Fucoidan, a sulfated α-L-Fucan from brown seaweed, is reshaping translational oncology and immunology. This thought-leadership article synthesizes advanced mechanistic insights—spanning apoptosis induction, immune modulation, and gut–liver axis repair—with strategic guidance for researchers. Moving beyond standard product pages, we detail experimental parameters and cross-domain opportunities, positioning APExBIO’s high-purity Fucoidan as an indispensable tool for next-generation studies.

• Docosahexaenoic Acid (DHA): Advanced Mechanisms in Neuroprot

  2026-07-29

  Explore how Docosahexaenoic Acid (DHA) drives neuroprotection by modulating hippocampal lipid metabolism and synaptic function. Discover unique mechanistic insights that inform advanced research protocols and distinguish this analysis from existing literature.

• S Tag Peptide (A6007): Technical Guidance for Fusion Tag Use

  2026-07-28

  S Tag Peptide (A6007) enables reliable protein solubility improvement, affinity purification, and antibody-based detection in recombinant protein workflows. It is best suited for aqueous protocols with validated anti-S-Tag reagents and should be avoided if ethanol solubility or long-term solution storage is required.

• Clozapine’s Neuropharmacology: Integrating ERK1/2 Activation

  2026-07-28

  Explore how Clozapine, a leading atypical antipsychotic medication, uniquely modulates ERK1/2 signaling and the EGF receptor in prefrontal neurons—bridging receptor pharmacology with emerging models of schizophrenia. This article provides advanced mechanistic insight and experimental guidance beyond standard protocols.

7917 records 4/528 page Previous Next 12345 下5页 Last page